Global private equity healthcare specialist ARCHIMED has acquired and simultaneously merged US-based Symbio, and Germany-based Proinnovera in an all-equity deal. Symbio and Proinnovera are Contract Research Organizations, offering cost saving, time-efficient outsourced services for dermatological therapy formulation and clinical trial testing. The merged group, Symbio Proinnovera, provides consulting, testing and clinical research through every development stage, from conception to global regulatory approval and commercialization. After decades of running dermatology trials, both companies have built valuable data bases that focus and shorten trials in this therapeutic area. Symbio and Proinnovera were respectively founded in 2002 and 1997.
Read the full article: ARCHIMED Creates a Leading Specialized Dermatological-Focused CRO via the Simultaneous Purchase & Merger of Symbio and Proinnovera //
Source: https://www.archimed.group/news/archimed-creates-a-leading-specialized-dermatological-focused-cro-via-the-simultaneous-purchase-merger-of-symbio-and-proinnovera